Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites

Drug Metabolism and Disposition

Volumn 33, Issue 12, 2005, Pages 1911-1919

  Ma, Shen Feng ^a   Anraku, Makoto ^a   Iwao, Yasunori ^a   Yamasaki, Keishi ^b   Kragh Hansen, Ulrich ^c   Yamaotsu, Noriyuki ^d   Hirono, Shuichi ^d   Ikeda, Toshihiko ^e   Otagiri, Masaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

^c AARHUS UNIVERSITY   (Denmark)

^d KITASATO UNIVERSITY   (Japan)

^e DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 BUTYLAMINOBENZOIC ACID; 4 NITROPHENOL; 4 NITROPHENYLACETIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ASPARAGINE DERIVATIVE; BENZOIC ACID DERIVATIVE; DANSYLASPARAGINE; DIAZEPAM; HISTIDINE; HUMAN SERUM ALBUMIN; IBUPROFEN; LYSINE; MUTANT PROTEIN; OLMESARTAN; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; CATALYSIS; COMPARATIVE STUDY; COMPUTER MODEL; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; ENTROPY; HUMAN; HYPOTHESIS; LIGAND BINDING; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; THERMODYNAMICS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BINDING SITES; CATALYSIS; HUMANS; HYDROLYSIS; IMIDAZOLES; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; SERUM ALBUMIN; TETRAZOLES; THERMODYNAMICS;

EID: 28244480803     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.006163     Document Type: Article

References (33)

1. Brousil JA and Burke JM (2003) Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 25:1041-1055.
2. Chen RF (1967) Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 242:173-181.
3. Curry S, Mandelkow H, Brick P, and Franks N (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 5:827-835.
4. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM Jr, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, and Kollman PA (1995) A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J Am Chem Soc 117:5179-5197.
5. Fehske KJ, Müller WE, and Wollert U (1978) The modification of the lone tryptophan residue in human serum albumin by 2-hydroxy-5-nitrobenzyl bromide. Characterization of the modified protein and the binding of L-tryptophan and benzodiazepines to the tryptophan-modified albumin. Hoppe-Seylers Z Physiol Chem 359:709-717.
6. Fehske KJ, Schläfer U, Wollert U, and Müller WE (1982) Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone. Mol Pharmacol 21:387-393.
7. Fersht A (1998) Structure and Mechanism in Protein Science, Freeman, New York.
8. Gasteiger J and Marsili M (1980) Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 36:3219-3228.
9. Gasteiger J and Marsili M (1981) Prediction of proton magnetic resonance shifts: the dependence on hydrogen charges obtained by iterative partial equalization of orbital electronegativity. Organ Magn Reson 15:353-360.
10. Gounaris AD and Perlmann GE (1967) Succinylation of pepsinogen. J Biol Chem 242:2739-2745.
11. Haynes R, Osuga DT, and Feeney RE (1967) Modification of amino groups in inhibitors of proteolytic enzymes. Biochemistry 6:541-547.
12. He XM and Carter DC (1992) Atomic structure and chemistry of human serum albumin. Nature (Lond) 358:209-215.
13. Ikeda K and Kurono Y (1986) Enzymatic activity and drug binding activity of human serum albumin. Yakugaku Zasshi 106:841-855.
14. 1-Acid Glycoprotein 173-180.
15. Koike H, Sada T, and Mizuno M (2001) In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens Suppl 19:1:S3-S14.
16. Kragh-Hansen U (1991) Octanoate binding to the indole- and benzodiazepine-binding region of human serum albumin. Biochem J 273:641-644.
17. Kragh-Hansen U, Chuang VTG, and Otagiri M (2002) Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 25:695-704.
18. Kurono Y, Yamada H, and Ikeda K (1982) Effects of drug binding on the esterase-like activity of human serum albumin. V. Reactive site towards substituted aspirins. Chem Pharm Bull 30:296-301.
19. Marsili M and Gasteiger J (1980) Pi-Charge Distributions from Molecular Topology and Pi-Orbital Electronegativity. Croat Chem Acta 53:601-614.
20. Means GE and Bender ML (1975) Acetylation of human serum albumin by p-nitrophenyl acetate. Biochemistry 14:4989-4994.
21. Neutel JM (2001) Clinical Studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 87 (8A):37C-43C.
22. Ozeki Y, Kurono Y, Yotsuyanagi T, and Ikeda K (1980) Effects of drug binding on the esterase activity of human serum albumin: inhibition modes and binding sites of anionic drugs. Chem Pharm Bull 28:535-540.
23. Peters T Jr (1996) All about Albumin, Biochemistry, Genetics and Medical Applications, Academic Press, San Diego.
24. Petitpas I, Bhattacharya AA, Twine S, East M, and Curry S (2001) Crystal structure analysis warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem 276:22804-22809.
25. Purcel WP and Singer JA (1967) A brief review and table of semiempirical parameters used in the Hüeckel molecular orbital method. J Chem Eng Data 12:235-246.
26. Rarey M, Kramer B, Lengauer T, and Klebe G (1996) A fast flexible docking method using incremental construction algorithm. J Mol Biol 261:470-489.
27. Roosemont JL (1978) Reaction of histidine residues in proteins with diethylpyrocarbonate: differential molar absorptivities and reactivities. Anal Biochem 88:314-320.
28. Sakurai Y, Ma SF, Watanabe H, Yamaotsu N, Hirono S, Kurono Y, Kragh-Hansen U, and Otagiri M (2004) Esterase-like activity of serum albumin: characterization of its structural chemistry using p-nitrophenyl esters as substrates. Pharm Res (NY) 21:285-292.
29. Sokolovsky M, Riordan JF, and Vallee BL (1966) Tetranitromethane. A reagent for the nitration of tyrosyl residues in proteins. Biochemistry 5:3582-3589.
30. Sugio S, Kashima A, Mochizuki S, Noda M, and Kobayashi K (1999) Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 12:439-446.
31. Watanabe H, Tanase S, Nakajou K, Maruyama T, Kragh-Hansen U, and Otagiri M (2000) Role of Arg-410 and Tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem J 349:813-819.
32. Watanabe H, Yamasaki K, Kragh-Hansen U, Tanase S, Harada K, Suenaga A, and Otagiri M (2001) In vitro and in vivo properties of recombinant human serum albumin from Pichia pastoris purified by a method of short processing time. Pharm Res (NY) 18:1775-1781.
33. Yamasaki K, Maruyama T, Kragh-Hansen U, and Otagiri M (1996) Characterization of site I on human serum albumin: concept about the structure of a drug binding site. Biochim Biophys Acta 1295:147-157.